NPCE vs RCEL: stock comparison and AI forecast
Neuropace Inc (NPCE) and Avita Medical, Inc. (RCEL) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
NPCE Neuropace Inc
- Price
- $12.69 -34.2% · 6M
- Market Cap
- $436M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
RCEL Avita Medical, Inc.
- Price
- $15.68 +275.1% · 6M
- Market Cap
- $485M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- RCEL is 1.1 times larger than NPCE by market capitalization ($485M against $436M).
- Over the last six months RCEL returned +275.1% and NPCE -34.2%.
- NPCE turns -19.3% of its revenue into net income, against -42.6% for RCEL.
- Both companies share the SEC industry classification Surgical & Medical Instruments & Apparatus.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | NPCE | RCEL |
|---|---|---|
| Market Cap | $436M | $485M |
| P/B Ratio | 36.66x | – |
| EPS | $-0.58 | $-1.35 |
| Book Value/Share | $0.35 | – |
| Revenue/Share | $2.88 | $2.74 |
| FCF/Share | $-0.34 | $-0.38 |
Profitability & Margins
| Metric | NPCE | RCEL |
|---|---|---|
| ROE | -160.8% | – |
| ROA | -19.7% | -77.2% |
| ROIC | -18.9% | -120.8% |
| Gross Margin | 79.6% | 82.4% |
| Operating Margin | -15.3% | -33.9% |
| Net Margin | -19.3% | -42.6% |
| EBT Margin | -15.3% | -42.6% |
| Tax Rate | 0.0% | -0.2% |
Financial Health
| Metric | NPCE | RCEL |
|---|---|---|
| Current Ratio | 4.94x | 1.20x |
| Quick Ratio | 3.91x | 0.99x |
| D/E Ratio | 7.16x | – |
| Financial Leverage | 8.16x | – |
| Interest Coverage | -3.7x | -1.8x |
| Working Capital | $69M | $5M |
Cash Flow
| Metric | NPCE | RCEL |
|---|---|---|
| Operating Cash Flow | -$11M | -$13M |
| Free Cash Flow | -$12M | -$12M |
| Capital Spending | -$370K | $1M |
| FCF/Sales | -11.8% | -13.8% |
| CapEx/Sales | 0.4% | 1.2% |
Operational Efficiency
| Metric | NPCE | RCEL |
|---|---|---|
| Asset Turnover | 1.02x | 1.81x |
| Receivables Turnover | 6.6x | 8.2x |
| Inventory Turnover | 1.1x | 3.1x |
| Fixed Assets Turnover | 79.5x | 11.5x |
| Days Sales Outstanding | 55 days | 45 days |
| Days Inventory | 328 days | 117 days |
| Payables Period | 76 days | – |
| Cash Conversion Cycle | 307 days | – |
Income Statement
| Metric | NPCE | RCEL |
|---|---|---|
| Total Revenue | $99M | $85M |
| Operating Income | -$15M | -$29M |
| Net Income | -$19M | -$36M |
| R&D Expense | $28M | $21M |
| SG&A Expense | $106M | $86M |
| Cost of Goods Sold | $20M | $15M |
Dividend & Shareholder Information
| Metric | NPCE | RCEL |
|---|---|---|
| Shares Outstanding | 34M | 31M |
NPCE vs RCEL: stock comparison and AI forecast
Which is bigger, NPCE or RCEL?
RCEL is 1.1 times larger than NPCE by market capitalization ($485M against $436M).
Which stock performed better over the last six months, NPCE or RCEL?
Over the last six months RCEL returned +275.1% and NPCE -34.2%.
Which one does Intratio's AI model rank higher, NPCE or RCEL?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.